Indian Pharmacopoeia Commission Issues Drug Safety Alert on Metfal

Drug Safety Alert on Metfal

Recently, the Indian Pharmacopoeia Commission (IPC) issued a drug safety alert regarding Metfal, a widely used painkiller for menstrual cramps and arthritis. This alert comes as a result of concerns raised about the potential risks associated with the use of Metfal and aims to ensure the safety of patients who rely on this medication for pain relief.

Metfal, also known by its generic name, Methylfenac, is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for the management of pain and inflammation. It is often used to alleviate symptoms associated with menstrual cramps and various forms of arthritis, including osteoarthritis and rheumatoid arthritis.

Its symptoms include skin rash, fever, haematological abnormalities, internal organ involvement, which can manifest two to eight weeks after drug intake, and lymphadenopathy.Meftal-Spas is commonly prescribed for a variety of conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever, and dental pain.

Healthcare professionals and patients are advised to be vigilant for signs of DRESS syndrome and other adverse drug reactions.If such symptoms occur, they should be reported promptly to the national coordination centre of the Pharmacovigilance Programme of India (PvPI) through various channels provided by the IPC.

The IPC’s drug safety alert highlights the need for caution when using Metfal due to the potential risks it may pose to patients. It is crucial for healthcare professionals and patients alike to be aware of these risks and take appropriate measures to ensure the safe use of this medication.

One of the primary concerns raised by the IPC is the potential for gastrointestinal complications associated with the use of Metfal. NSAIDs, including Metfal, have been known to cause stomach ulcers, bleeding, and other gastrointestinal issues. These complications can be particularly severe in individuals with a history of gastrointestinal disorders or those who take high doses of the medication for an extended period.

Additionally, the IPC’s alert emphasizes the importance of monitoring liver function in patients using Metfal. Prolonged use of NSAIDs, including Metfal, has been associated with liver damage in some cases. Regular liver function tests are recommended for patients on long-term Metfal therapy to detect any potential abnormalities early on.

Furthermore, the IPC advises healthcare professionals to exercise caution when prescribing Metfal to patients with a history of cardiovascular disease. Studies have suggested that long-term use of NSAIDs, including Metfal, may increase the risk of heart attacks, strokes, and other cardiovascular events. It is essential for healthcare providers to consider the individual patient’s cardiovascular health and weigh the benefits against the potential risks before prescribing Metfal.

Patients who are currently using Metfal are encouraged to consult their healthcare provider to discuss any concerns or questions they may have. It is crucial for patients to understand the potential risks associated with this medication and to follow their healthcare provider’s guidance regarding its safe and appropriate use.

The IPC’s drug safety alert on Metfal serves as a reminder to healthcare professionals and patients alike to remain vigilant about the potential risks associated with the use of medications. It is essential to prioritize patient safety and ensure that the benefits of any medication outweigh the potential risks.

In conclusion, the Indian Pharmacopoeia Commission’s drug safety alert on Metfal highlights the need for caution when using this widely prescribed painkiller. The alert draws attention to the potential gastrointestinal, liver, and cardiovascular risks associated with the use of Metfal. Healthcare professionals and patients should remain informed about these risks and take appropriate measures to ensure the safe use of this medication. By prioritizing patient safety and staying updated on drug safety alerts, we can collectively work towards minimizing the potential risks associated with medication use.